Cargando…
Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
COVID-19 is a devastating global pandemic around the world. While the majority of infected cases appear mild, in some cases individuals present respiratory complications with possible serious lung damage. There are no specific treatments for COVID-19 as yet, though a number are under evaluation, inc...
Autores principales: | Sayad, Babak, Sobhani, Mahsa, Khodarahmi, Reza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IMSS. Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188631/ https://www.ncbi.nlm.nih.gov/pubmed/32387040 http://dx.doi.org/10.1016/j.arcmed.2020.04.018 |
Ejemplares similares
-
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
por: Sacramento, Carolina Q., et al.
Publicado: (2017) -
The ACE2 as a “rescue protein” or “suspect enzyme” in COVID-19: possible application of the “engineered inactive hrsACE2” as a safer therapeutic agent in the treatment of SARS-CoV-2 infection
por: Khodarahmi, Reza, et al.
Publicado: (2020) -
Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
por: Sacramento, Carolina Q., et al.
Publicado: (2017) -
Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery
por: Abdulaziz, Leena, et al.
Publicado: (2022) -
Repurposing of approved cardiovascular drugs
por: Ishida, Junichi, et al.
Publicado: (2016)